Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus

Journal of Clinical Pharmacology

Volumn 36, Issue 11, 1996, Pages 1012-1021

  Sambol, Nancy C ^a   Chiang, Janie ^a   O'Conner, Michael ^b   Liu, Chui Y ^a   Lin, Emil T ^d   Goodman, Anita M ^c   Benet, Leslie Z ^a   Karam, John H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Lipha Pharmaceuticals Inc   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; SINGLE BLIND PROCEDURE;

EID: 0030443768     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009603601105     Document Type: Article

References (32)

1. Schäfer G: Biguanides: a review of history, pharmacodynamics and therapy. Diabete Métabol 1983;9:148-163.
2. Phillips PJ, Thomas DW, Harding PE: Biguanides and lactic acidosis (letter). Br Med J 1977;1:234.
3. Bergman U, Boman G, Wiholm BE: Epidemiology of adverse drug reactions to phenformin and metformin. Br Med J 1978;2:464-466.
4. Hermann LS: Metformin: a review of its pharmacological properties and therapeutic use. Diabete Métabol 1979;5:233-245.
5. Hermann LS, Melander A: Biguanides: basic aspects and clinical uses. In, Alberti KGMM, DeFronzo RA, Keen H, Zimmet P (eds.): International Textbook of Diabetes Mellitus. New York: John Wiley & Sons, 1992;773-795.
6. Bailey CJ: Metformin: an update. Gen Pharmacol 1993; 24:1299-1309.
7. Bailey CJ, Nattrass M: Treatment: metformin. Baillieres Clin Endocrinol Metab 1988;2:455-476.
8. Frayn KN: Effects of metformin on insulin resistance after injury in the rat. Diabetologia 1976;12:53-60.
9. Nattrass M, Todd PG, Hinks L, Lloyd B, Alberti KGMM: Comparative effects of phenformin, metformin and glibenclamide on metabolic rhythms in maturity-onset diabetics. Diabetologia 1977;13:145-152.
10. Noel M: Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. Res Clin Forums 1979; 1:33-44.
11. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF: Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12:235-246.
12. Pentikäinen PJ, Neuvonen PJ, Penttila A: Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979;16:195-202.
13. Sirtori CR, Franceschini G, Gall-Kienle M, Cihetti G, Galli G, Bondioli A, Conti F: Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978;24:683-693.
14. Guzman NJ: Hypertension and kidney disease of diabetes mellitus. J Florida Med Assoc 1991;78:751-753.
15. Mauer SM, Steffes MW, Brown DM: The kidney in diabetes. Am J Med 1981;70:603-612.
16. Garber AJ, Campese VM, Franz MJ, Hoogwerf B, Levy J, Mitch W, et al: Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetic Care 1994;17:1357-1361.
17. Friedman E: Diabetic renal disease. In, Rifkin H, Porte D (eds.): Diabetes Mellitus: Theory and Practice. Fourth edition. New York: Elsevier, 1990;684-709.
18. Vermeulen A, Rottiers R: Influence of dimethyl biguanide (metformin) on carbohydrate metabolism in obese, non-diabetic women. Diabetologia 1972;8:8-11.
19. Sulaiman WR Johnson RH: The effects of phenformin and metformin on fat and carbohydrate metabolism. Acta Diabetol Lat 1977;14:129-136.
20. Oberdisse K: Der Wirkungsmechanismus der Biguanide auf Grund klinisch-experimenteller Untersuchungen und Die klinische Anwendung der Biguanide. In, Oberdisse (ed.): Handbunch der inneren Medizin. Band VII/2B, Diabetes mellitus. Berlin:Springer Verlag, 1977;983-997, 999-1066.
21. Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG: Kidney function and age are both predictors of metformin pharmacokinetics. J Clin Pharmacol 1995;35:1094-1102.
22. Sambol NC, Brookes LG, Chiang J, Goodman AM, Lin ET, Liu CY, Benet LZ: Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol 1996;4:510-512.
23. Pentikäinen PJ: Bioavailability of metformin: comparison of solution, rapidly dissolving table, and three sustained release products. Int J Clin Pharmacol Ther Toxicol 1986;24:213-220.
24. Bailey CJ: Biguanides and NIDDM. Diabetes Care 1992;15:755-772.
25. Stowers JM: Oral treatment in diabetes. Clin Endocrin Metab 1972;1:721-750.
26. Muntoni S: Inhibition of fatty acid oxidation by biguanides: implications for metabolic physiopathology. Adv Lipid Res 1974;12:311-377.
27. Stout RW: Diabetes and atherosclerosis: the role of insulin. Diabetologia 1979;16:141-150.
28. Hundal HS, Ramlal T, Reyes R, Leiter LA, Klip A: Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 1992;131:1165-1173.
29. Sarabia V, Lam L, Burdett E, Leiter LA, Klip A: Glucose transport in human skeletal muscle cells in culture: stimulation by insulin and metformin. J Clin Invest 1992;90:1386-1395.
30. Matthaei S, Greten H: Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane. Diabete Métabol 1991;17:150-158.
31. Klip A, Guma A, Ramlal T, Bilan PJ, Lam L, Letter LA: Stimulation of hexose transport by metformin in L6 muscle cells in culture. Endocrinology 1992;130:2535-2544.
32. Sirtori CR, Pasik C: Re-evaluation of a biguanide metformin: mechanism of action and tolerability. Pharmacol Res 1994;3:187-228.